{
  "model": "qwen/qwen3.6-35b-a3b",
  "started_at": "2026-06-05T22:25:23.005Z",
  "system_prompt": "You are Analyst, the thesis-judgment stage of an AI trade-ideas pipeline.\n\nScout has already gathered a JSON dossier of scoring_inputs. Your job is to\nSCORE the dossier against the methodology rubric and either draft a\nhigh-conviction idea, draft a clearly labeled paper-tracked research idea,\nor skip.\n\nOPTION B (skip) IS THE EXPECTED DEFAULT. The pipeline publishes normal\nrecommendation-grade ideas rarely and only when something clears a high bar.\nMost dossiers should return\n{ \"skip\": true, \"reason\": \"...\", \"score\": <num> }. Mediocre publishes burn\nDevil's Advocate budget and create credibility risk on the public site.\nPaper-tracked ideas are a separate measurement lane: they are zero-position,\nlow-confidence research setups used to learn whether the model's medium-grade\nsignals work over time. They must never read like a buy/sell recommendation.\n\nLOOK AT THE FULL STRUCTURE MENU. Even when Scout says 'no asymmetric long\nopportunity exists' (verdict=range_bound_or_income), there may be a clear\nINCOME structure (covered call against the high; strangle inside an IV-\nelevated band; CSP at a downside-defended strike). Don't reflex-skip just\nbecause long_stock isn't attractive. Read the dossier looking for what\nSHAPE OF TRADE fits, not just whether long is fits.\n\nSCORING RUBRIC (sum to max 100)\n\nA. SMART-MONEY CLUSTER (max 25) — from scoring_inputs.smart_money\n   • 10 pts if 3+ distinct insiders with open-market purchases (code P) in\n     last 90 days totaling ≥ $500K\n   • +3 pts if CEO is among the buyers\n   • +3 pts if CFO is among the buyers\n   • +2 pts if total purchases > $5M\n   • 5 pts for a known concentrated 13F initiation/add (Berkshire, Pershing\n     Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\n   • +3 pts if it's in the manager's top-3 positions\n   • 2 pts for politician STOCK Act recent buy\n   • +1 pt if multiple unrelated members bought within 30 days\n   • Penalty: −10 pts if material insider SELLING > BUYING in dollars\n\nB. OPTIONS FLOW / UOA (max 10) — from scoring_inputs.options_flow\n   • 4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish\n     and flow_strength ∈ {moderate, strong}\n   • 3 pts: bullish IV skew (call IV > put IV) consistent with thesis\n   • 2 pts: net_dollar_bias_pct > 30 (sustained call-side flow)\n   • 1 pt: large OI building at a defended price level\n   • Penalty: −5 pts if whale_put_blocks_otm ≥ 2 and bias is bearish\n     without a hedging explanation\n\nC. CATALYST (max 25) — from scoring_inputs.catalyst\n   • 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\n   • 8 pts: pending product launch / FDA / contract milestone in horizon\n   • 5 pts: recent guidance raise (last 90 days)\n   • 5 pts: quantifiable sector tailwind (named hyperscaler capex flowing\n     to this name in $)\n   Cap at 25 even if components add to more.\n\nD. MISPRICING (max 15) — from scoring_inputs.mispricing\n   • 5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating\n     earnings)\n   • 4 pts: EV/EBITDA ≥ 30% below sector median\n   • 4 pts: FCF yield ≥ 7% with stable FCF\n   • 5 pts: SOTP gap ≥ 25% (replaces one of the above)\n   Cap at 15.\n\nE. QUALITY (max 15) — from scoring_inputs.quality\n   • 5 pts: ROIC ≥ 15% (or trending there)\n   • 5 pts: gross margin expanding ≥ 3pp YoY\n   • 5 pts: net debt / EBITDA ≤ 2x (or net cash)\n\nF. MOMENTUM/TECHNICAL (max 10) — from scoring_inputs.technical\n   • 3 pts: above both 50DMA and 200DMA\n   • 4 pts: 12-1 month price return positive AND beating sector\n   • 2 pts: RSI 14 in 40-65 zone\n   • 1 pt: MACD bullish cross in last 30 days\n\nRISK CLASS — choose one based on the dossier's market_cap field:\n   \"core\"        — market_cap > $5B. Standard methodology sizing.\n   \"asymmetric\"  — market_cap ≤ $5B (small-cap moonshot). 90%+ of these\n                   bets lose money or go to zero; the few that work pay\n                   for the rest. Position sizing is far more conservative\n                   to fit the variance.\n\nTHRESHOLDS — depend on risk_class\n\n  CORE risk_class:\n   ≥ 80    Publish, confidence 5, position size cap 4-5%\n   70-79   Publish, confidence 4, position size cap 2.5-3.0%\n   60-69   Publish, confidence 3, position size cap 1.5-2.0%\n   45-59   Paper-track if no hard anti-signal and the thesis is specific,\n           measurable, and falsifiable; otherwise skip\n   < 45    Skip\n\n  ASYMMETRIC risk_class — strict sizing:\n   ≥ 80    Publish, confidence 5, position size cap 1.5%\n   70-79   Publish, confidence 4, position size cap 1.0%\n   60-69   Publish, confidence 3, position size cap 0.5%\n   45-59   Paper-track only if there is a concrete dated catalyst or\n           measurable event path; otherwise skip\n   < 45    Skip\n   Structure must be long_stock (options structures are wrong shape for\n   moonshots; Compliance enforces this in code).\n\nANTI-SIGNAL GATES (any one of these forces skip regardless of score):\n   • Going-concern audit qualification\n   • Pending material litigation (DOJ/SEC enforcement, class action with merit)\n   • Customer concentration > 30%\n   • Convertible/warrant overhang creating dilution > 10% of float\n   • Accounting irregularities (restatements, auditor changes)\n   • Avg daily volume < $5M (liquidity gate)\n   • Pump-and-dump signals (sudden volume + chat-room mentions)\n\nIf scoring_inputs has anti_signals_present non-empty, treat each entry as a\ngate; skip unless you can articulate WHY it doesn't apply to this case.\n\nEDGE CHECK (philosophical, not numeric)\n\nAfter scoring, ask: \"What does this idea say that the market doesn't already\nknow?\" If the answer is generic (it's cheap, AI is a tailwind, technicals\nlook great), the score is misleading — skip even if numerical score is 65.\nReal edge means a specific data point or interpretation the market missed.\n\nPAPER-TRACKING LANE (educational measurement, not advice)\n\nUse this lane for score 45-59 dossiers that are not strong enough for a\nnormal publication but are specific enough to evaluate later. Requirements:\n   • draft.paper_track MUST be true\n   • headline MUST begin with \"Paper Track:\"\n   • thesis_short MUST explicitly say this is a paper-tracked research setup,\n     not an actionable recommendation\n   • risk.position_size_pct MUST be 0\n   • confidence MUST be 1 or 2 (2 only when score ≥55)\n   • exit.time_horizon_months MUST be present so Monitor can close it\n   • use long_stock unless the dossier gives complete, current option\n     contract data for the chosen income structure\n\nDo not paper-track dossiers with methodology anti-signals, stale numbers,\nmissing sources, unverified catalyst dates, or generic \"cheap/AI/tailwind\"\nstories. Skip those.\n\nUPSIDE TARGET\n\nThe desk is looking for setups with a plausible 20%+ return target. For\nlong_stock, exit.target_price should be at least 20% above entry.price_at_idea\nunless the idea is explicitly a paper-tracked post-event study. If the\nsource-backed upside is less than 20%, skip rather than publishing a low-upside\nidea.\n\nSCOUT VERDICT → STRUCTURE GUIDANCE\n\nRead scoring_inputs and Scout's verdict together. The verdict tells you\nWHICH structures Scout thinks are in scope for this name:\n\n  verdict='promising'              → long_stock | csp (for asymmetric long)\n  verdict='range_bound_or_income'  → cc | strangle | csp on pullback\n                                     (DON'T default to long_stock — Scout\n                                      already said this isn't an asymmetric\n                                      long. Look at IV elevated → strangle;\n                                      stock at 52w high, fundamentals healthy\n                                      → cc against implicit long; pullback\n                                      thesis with cash → csp)\n  verdict='bearish_setup'          → naked_call (rarely; respect ceiling)\n\nIf Scout supplied structure_hints[], they're a starting point. You can\noverride with reasoning, but if you go OUTSIDE the verdict's natural set,\nexplain why in thesis_long.\n\nSTRUCTURE SELECTION — full menu:\n\n   long_stock   — multi-quarter asymmetric thesis, IV not elevated, want\n                  full upside participation\n   csp          — bullish, want to own at strike, IV elevated, ann yield ≥15%\n   cc           — range-bound or mildly bullish, IV elevated, on top of long\n                  stock leg, if-called return ≥15% ann\n   strangle     — RANGE-BOUND thesis with elevated IV. Sell OTM call + OTM\n                  put. Need: comfortable owning at put_strike, no parabolic\n                  upside expectation. Ann yield ≥12%. Compute and emit\n                  breakeven_high (call_strike + total_premium) and\n                  breakeven_low (put_strike - total_premium).\n   naked_put    — same setup as CSP but using margin. ~2x yield, margin call\n                  risk. Only for margin-equipped accounts. Note explicitly.\n   naked_call   — bearish setup with elevated IV. UNCAPPED loss if rally.\n                  Confidence ceiling 4 (Compliance enforces). Requires\n                  explicit upside-shock thesis + defense plan in conditions.\n\nMatch the structure to the thesis shape — don't reach for naked options\njust because the premium is fatter. Most candidates are best as long_stock\nor CSP. Strangles only when you have a clear range thesis backed by IV\nand fundamentals.\n\nIF YOU SKIP — output exactly:\n  {\n    \"skip\": true,\n    \"score\": <0-100 composite>,\n    \"score_breakdown\": {\n      \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n      \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n    },\n    \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n  }\n\nIF YOU PROCEED — output a draft idea matching this schema (this is the same\nschema the published site renders from):\n\n{\n  \"skip\": false,\n  \"score\": <0-100 composite>,\n  \"score_breakdown\": {\n    \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n    \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n  },\n  \"draft\": {\n    \"slug\": \"YYYY-MM-DD-symbol-keyphrase\",\n    \"paper_track\": false,\n    \"symbol\": \"TICKER\",\n    \"company\": \"Full name\",\n    \"sector\": \"semis-ai-infra\" | \"small-cap-asymmetric\",\n    \"risk_class\": \"core\" | \"asymmetric\",\n    \"headline\": \"Punchy 1-line — the news angle on the thesis\",\n    \"thesis_short\": \"1 sentence — why this trade exists.\",\n    \"thesis_long\": [\n      \"Opening paragraph framing the setup.\",\n      \"## Catalyst\",\n      \"Detailed catalyst narrative.\",\n      \"## Why the market is mispricing this\",\n      \"Edge explanation, citing dossier facts.\",\n      \"## Numbers\",\n      \"- Bullet 1 with concrete numbers from the dossier\",\n      \"- Bullet 2\",\n      \"## Risk\",\n      \"Honest description of what could go wrong.\"\n    ],\n    \"structure\": {\n      \"type\": \"long_stock\" | \"csp\" | \"cc\" | \"strangle\" | \"naked_put\" | \"naked_call\",\n      \"long_stock\":   { \"entry_zone_low\": <num>, \"entry_zone_high\": <num>, \"shares_per_unit\": 100 },\n      \"csp\":          { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"if_assigned_basis\": <num> },\n      \"cc\":           { \"underlying_basis\": <num>, \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"if_called_return_pct\": <num> },\n      \"strangle\":     { \"call_strike\": <num>, \"put_strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"call_premium_target\": <num>, \"put_premium_target\": <num>, \"total_premium_target\": <num>, \"breakeven_high\": <num>, \"breakeven_low\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_note\": \"...\" },\n      \"naked_put\":    { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_per_contract\": <num>, \"margin_estimate_per_contract\": <num>, \"warning\": \"...\" },\n      \"naked_call\":   { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss\": \"UNLIMITED\", \"warning\": \"...\" }\n    },\n    \"entry\": {\n      \"price_at_idea\": <last_close from dossier>,\n      \"conditions\": \"How/when to enter — e.g., 'Open starter on pullback to MA50.'\"\n    },\n    \"exit\": {\n      \"target_price\": <num or null for options structures>,\n      \"time_horizon_months\": <int 3-12>,\n      \"stop_conditions\": \"Specific signal(s) that trigger a close.\"\n    },\n    \"risk\": {\n      \"bear_case\": \"Honest, specific bear case (not generic 'market could fall').\",\n      \"what_breaks_thesis\": \"Specific event/data that invalidates the call.\",\n      \"position_size_pct\": <0.0 for paper_track, otherwise 0.5 to 5.0 conviction-weighted>\n    },\n    \"sources\": [\n      { \"label\": \"...\", \"url\": \"...\" }\n    ],\n    \"confidence\": <1-5, conservative>,\n    \"analyst\": \"research-desk\",\n    \"scout_model\": \"minimax/minimax-m2.7\",\n    \"analyst_model\": \"qwen/qwen3.6-35b-a3b\",\n    \"devils_advocate_verdict\": null\n  }\n}\n\nONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that\nsub-object. Leave the others null/omitted.\n\nALL NUMBERS must be drawn from the dossier or computable from it. Do not\ninvent prices, strikes, premiums.\n\nOUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.",
  "user_prompt": "CURRENT DATE: 2026-06-05. THE YEAR IS 2026.\nDATE RULES — read before writing ANY date:\n  - Every option expiry, earnings date, catalyst date, and DTE you state MUST use the year 2026 or later. Do NOT write 2025 dates — your training prior is stale.\n  - Every option expiry MUST be a real FUTURE date relative to 2026-06-05. Copy expiries verbatim from options_expiries()/the dossier — never infer a year from memory.\n  - Before writing a date, check it: if it is earlier than 2026-06-05, it is WRONG — re-read the live tool output.\n\nHere is the dossier from Scout. Decide: skip or draft.\n\n\nLESSONS LEARNED: none yet.\n\nDOSSIER:\n{\n  \"symbol\": \"ABSI\",\n  \"company\": \"Absci Corporation\",\n  \"investigation_summary\": \"Absci is an AI-native clinical-stage biopharma whose lead program ABS-201 targets prolactin receptor (PRLR) for androgenetic alopecia and endometriosis. The June 5 8-K was routine (annual meeting), but the real near-term catalyst is Phase 1/2a HEADLINE trial interim proof-of-concept data expected H2 2026 — all four SAD cohorts have been dosed with favorable safety, MAD dosing initiated. Chief Innovation Officer Andreas Busch made a substantial open-market purchase of 100,000 shares at $2.29 in March 2026 (~$229K), and options flow is overwhelmingly bullish call-skew. However, the stock has already run ~134% YTD and sits near its 52-week high, trading above both MAs with no obvious entry point for a new long position without pulling back.\",\n  \"verdict\": \"range_bound_or_income\",\n  \"confidence_in_data\": 5,\n  \"structure_hints\": [\n    \"cc\",\n    \"strangle\",\n    \"csp\"\n  ],\n  \"business_snapshot\": \"Absci Corporation is a clinical-stage biopharma using generative AI (Origin-1 de novo design model) to develop differentiated antibody therapeutics. The company's lead program ABS-201, an anti-prolactin receptor (PRLR) antibody with extended half-life, is in the HEADLINE Phase 1/2a trial for androgenetic alopecia and planned for Phase 2 in endometriosis — two massive unmet-need indications with no approved disease-modifying therapies. Absci also has ABS-101 (Phase 1, seeking partner), early-stage oncology/immunology assets including ABS-301, ABS-501, and newly added ABS-202. The company generated only $215K in Q1 2026 partner revenue; it is cash-funded with ~$125.7M in cash vs ~$4.4M debt, burning roughly $100M/year.\",\n  \"scoring_inputs\": {\n    \"smart_money\": {\n      \"insider_open_market_purchases_90d\": [\n        {\n          \"insider\": \"Andreas Busch\",\n          \"role\": \"Chief Innovation Officer\",\n          \"amount_usd\": 229000,\n          \"date\": \"2026-03-12\",\n          \"source_url\": \"https://www.sec.gov/Archives/edgar/data/1672688/000167268826000049/xslF345X05/wk-form4_1773692239.xml\"\n        }\n      ],\n      \"insider_open_market_total_usd_90d\": 229000,\n      \"distinct_insider_buyers_90d\": 1,\n      \"ceo_buy_present\": false,\n      \"cfo_buy_present\": false,\n      \"material_insider_selling_90d_usd\": 0,\n      \"notable_13f_holders\": [\n        \"pending — v2\"\n      ],\n      \"politician_recent_buys\": [\n        \"pending — v2\"\n      ]\n    },\n    \"catalyst\": {\n      \"next_earnings_date\": \"2026-08-07T20:00:00.000Z\",\n      \"recent_eps_surprise_pattern\": \"Q1 2026 beat by +4.6% (-0.19 actual vs -0.199 est); Q4 2025 missed by -32.5%; pattern is inconsistent but recent trend improved\",\n      \"guidance_raise_in_last_90d\": false,\n      \"named_catalysts\": [\n        {\n          \"type\": \"product\",\n          \"description\": \"ABS-201 HEADLINE Phase 1/2a interim proof-of-concept data (exploratory efficacy endpoints) expected H2 2026; full PoC early 2027\",\n          \"date_or_window\": \"H2 2026\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1672688/000167268826000088/absi-20260331.htm\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"product\",\n          \"description\": \"ABS-201 Phase 2 endometriosis trial initiation planned Q4 2026\",\n          \"date_or_window\": \"Q4 2026\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1672688/000167268826000068/absi-20251231.htm\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"product\",\n          \"description\": \"All four SAD cohorts dosed; MAD cohort initiated — safety favorable (reported Q1 2026 earnings call, May 7 2026)\",\n          \"date_or_window\": \"Q2 2026 (completed)\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthcare/articles/absci-reports-business-updates-first-200500427.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"product\",\n          \"description\": \"Origin-1 de novo AI antibody design platform released January 2026; validates platform capability with atomically accurate binders for 'zero-prior' epitopes\",\n          \"date_or_window\": \"January 2026 (completed)\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1672688/000167268826000068/absi-20251231.htm\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"regulatory\",\n          \"description\": \"ABS-201 Phase 2 endometriosis initiation requires FDA IND clearance or equivalent; company plans to rely on HEADLINE safety/PK data package\",\n          \"date_or_window\": \"Q4 2026\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1672688/000167268826000068/absi-20251231.htm\"\n          ],\n          \"directional_bias\": \"ambiguous\"\n        }\n      ]\n    },\n    \"mispricing\": {\n      \"forward_pe\": -9.94,\n      \"sector_median_forward_pe\": null,\n      \"ev_to_ebitda\": -8.79,\n      \"sector_median_ev_to_ebitda\": null,\n      \"fcf_yield_pct\": -4.16,\n      \"sotp_gap_pct\": null,\n      \"narrative\": \"No traditional valuation multiples are meaningful for a pre-revenue, loss-making biotech. Market appears to be pricing in pipeline optionality — stock has run 134% YTD and analyst target median of $8.79 vs current $6.40 implies ~37% upside but that is already embedded after the run. At current levels near 52w high with binary Phase 1/2a data ahead, risk/reward for a directional long is uncertain.\"\n    },\n    \"quality\": {\n      \"roic_pct\": null,\n      \"gross_margin_trend_pp_yoy\": 0,\n      \"operating_margin\": -143.47,\n      \"net_debt_to_ebitda\": null,\n      \"balance_sheet_grade\": \"B+\"\n    },\n    \"technical\": {\n      \"above_50dma\": true,\n      \"above_200dma\": true,\n      \"rsi_14\": 58.5,\n      \"macd_recent_bullish_cross\": true,\n      \"12_1_momentum_vs_sector_pct\": 134.43\n    }\n  },\n  \"price_context\": {\n    \"last_close\": 6.4,\n    \"ytd_return_pct\": 134.43,\n    \"from_52w_high_pct\": -12.8\n  },\n  \"filings_reviewed\": [\n    {\n      \"form\": \"10-K\",\n      \"filed\": \"2026-03-24\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1672688/000167268826000068/absi-20251231.htm\",\n      \"key_takeaways\": [\n        \"FY 2025 filed March 24, 2026. $125.7M cash vs $4.4M debt as of Q1 2026 balance sheet context. Accumulated deficit $654M. ABS-201 HEADLINE trial initiated Dec 2025 in Australia; all four SAD cohorts completed with favorable safety; MAD cohort enrollment started Q2 2026. Phase 2 endometriosis planned Q4 2026. Origin-1 released Jan 2026. ABS-101 seeking partner after strategic prioritization to ABS-201. ABS-202 added as second anti-PRLR preclinical program.\"\n      ]\n    },\n    {\n      \"form\": \"10-Q\",\n      \"filed\": \"2026-05-07\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1672688/000167268826000088/absi-20260331.htm\",\n      \"key_takeaways\": [\n        \"Q1 2026: $215K partner revenue, net loss $(29.6M). R&D spend $19.3M (up from $16.4M YoY). Cash $125.7M. All four SAD cohorts completed; MAD cohort dosing initiated for AGA participants. EPS beat +4.6%. AMD collaboration premium of ~$2.5M amortized over 2026 as R&D credit.\"\n      ]\n    },\n    {\n      \"form\": \"8-K\",\n      \"filed\": \"2026-06-05\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1672688/000167268826000095/absc-20260604.htm\",\n      \"key_takeaways\": [\n        \"Annual meeting June 4, 2026: elected Prof Sir Menelas Pangalos and Daniel Rabinovitsj as Class II directors; ratified Ernst & Young as auditor for FY 2026. Routine corporate governance — no material new information.\"\n      ]\n    },\n    {\n      \"form\": \"8-K\",\n      \"filed\": \"2026-05-07\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1672688/000167268826000086/absc-20260507.htm\",\n      \"key_takeaways\": [\n        \"Q1 2026 results + business update. Press release + corporate presentation with pipeline updates. ABS-201 safety data favorable; PK modeling supports targeted dosing interval.\"\n      ]\n    }\n  ],\n  \"options_context\": {\n    \"expiries_examined\": [\n      \"2026-06-18\",\n      \"2026-07-17\",\n      \"2026-08-21\",\n      \"2026-11-20\",\n      \"2027-01-15\"\n    ],\n    \"iv_summary\": \"July 17 ATM call IV ~126%, ITM $5 strike call ~152%. OTM $3 put IV ~164%. Put/call ratio extremely low at 0.03 with net directional bias +$1.72M (call-heavy). V/OI spikes on deep OTM $3 call (V/OI=1920) and $5 call (V/OI=66). Top open interest calls at $8, $7 strikes — likely short-covering or speculative bullish.\"\n  },\n  \"competitive_landscape\": \"ABS-201 for AGA faces oral minoxidil/finasteride/dutasteride standard of care + pipeline candidates: Hope Medicine HMI-115, Veradermics VDPHL01, Pelage PP405, Cosmo Clascoterone. For endometriosis: no approved disease-modifying therapy; Hope Medicine HMI-115, Chugai AMY-109 also in non-hormonal antibody space. ABS-101 TL1A for IBD faces Merck MK-7240, Roche/Roivant RVT-3101, Sanofi/Teva TEV-48574. AI design competition: Generate Biomedicines, Xaira Therapeutics.\",\n  \"key_risks\": [\n    \"Binary Phase 1/2a data readout in H2 2026 could disappoint and trigger large drawdown given near-52w-high entry\",\n    \"Stock has run +134% YTD — significant mean-reversion risk if macro or sector headwinds hit\",\n    \"No current revenue; ~$125M cash with $100M+ annual burn = runway concerns without partnership financing\",\n    \"25.7% short interest float creates volatility amplifier on any negative catalyst\",\n    \"ABS-201 mechanism (PRLR antagonism) is genuinely underexplored — regulatory/clinical path carries novel risk\",\n    \"Origin-1 platform not yet commercially validated; de novo design against zero-prior epitopes is scientifically ambitious\"\n  ],\n  \"what_the_market_might_be_missing\": \"The CINO's March 2026 open-market purchase of $229K at ~$2.29 (stock now at $6.40, already up >170% on that position) suggests insider conviction about near-term clinical catalysts — but this also means the easy alpha is already captured. The real edge may be in the IV compression opportunity: with binary H2 2026 data catalyst priced into high vol, a structured strangle sale could capture premium while managing direction risk. Analyst consensus at $8.79 implies ~37% upside from here vs full PoC potential — not compelling for an uncapped-risk long given the binary nature of Phase 1/2a readout.\",\n  \"anti_signals_present\": [\n    \"dilution\",\n    \"cash_burn\",\n    \"low_liquidity\"\n  ],\n  \"sources\": [\n    {\n      \"label\": \"10-K FY2025\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1672688/000167268826000068/absi-20251231.htm\"\n    },\n    {\n      \"label\": \"10-Q Q1 2026\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1672688/000167268826000088/absi-20260331.htm\"\n    },\n    {\n      \"label\": \"8-K Annual Meeting June 4 2026\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1672688/000167268826000095/absc-20260604.htm\"\n    },\n    {\n      \"label\": \"Q1 2026 Earnings 8-K May 7 2026\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1672688/000167268826000086/absc-20260507.htm\"\n    },\n    {\n      \"label\": \"Insider Form 4 Busch March 12 2026\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1672688/000167268826000049/xslF345X05/wk-form4_1773692239.xml\"\n    },\n    {\n      \"label\": \"Q1 Earnings Press Release\",\n      \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/absci-reports-business-updates-first-200500427.html\"\n    }\n  ],\n  \"unfetched_signals\": [\n    \"13f_deltas\",\n    \"politician_trades\",\n    \"sentiment_score\"\n  ]\n}\n\nOutput ONLY the decision JSON described in the system prompt. Do NOT\ninclude <think>...</think> reasoning blocks — they eat the output token\nbudget and produce truncated, unparseable decisions.",
  "completions": [
    {
      "ts": "2026-06-05T22:26:06.751Z",
      "raw_content": "<think>The dossier is for ABSI (Absci Corporation), a clinical-stage biopharma.\nScoring:\nA. Smart-Money: 1 insider buyer (CINO) for $229K. Not 3+ distinct, not CEO/CFO, not >$5M. 0 pts.\nB. Options Flow: IV is extremely high (ATM call IV ~126%, OTM put IV ~164%). Put/call ratio extremely low (0.03). Net directional bias +$1.72M (call-heavy). High IV means options are expensive, but the dossier says \"range_bound_or_income\" and notes binary H2 2026 data catalyst priced into high vol. However, buying options here is terrible. Selling options (strangle/CC) might be the income play, but the dossier has anti_signals_present: [\"dilution\", \"cash_burn\", \"low_liquidity\"]. Low liquidity is a hard gate in the prompt (\"Avg daily volume < $5M (liquidity gate)\"). I don't have volume data, but \"low_liquidity\" is flagged. Also, cash burn and dilution are anti-signals.\nWait, let's check anti-signal gates: \"Avg daily volume < $5M (liquidity gate)\". The dossier flags \"low_liquidity\". I should treat this as a liquidity gate failure or at least a strong negative.\nAlso, \"dilution\" and \"cash_burn\" are anti-signals. The prompt says: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nDilution: clinical-stage biotechs typically have high dilution risk, but is it >10% of float? Not specified, but flagged.\nCash burn: $100M/year burn with $125M cash. Runway is ~1.25 years. High risk of dilution.\nLow liquidity: flagged.\nGiven the anti-signals, I should probably skip.\nLet's score it anyway to be thorough, but the anti-signals + lack of asymmetric upside + high IV + binary catalyst + low liquidity strongly point to SKIP.\nScore breakdown:\nA: 0 (only 1 insider, $229K)\nB: 2 (bullish IV skew, net call bias, but high IV makes selling attractive, not buying. I'll give 2 for call bias/skew)\nC: 8 (pending Phase 1/2a data H2 2026)\nD: 0 (pre-revenue, no meaningful multiples)\nE: 0 (loss-making, no ROIC/gross margin)\nF: 3 (above 50DMA/200DMA, RSI 58.5)\nTotal: ~13.\nAnti-signals: dilution, cash_burn, low_liquidity.\nVerdict: Skip.\nReason: Flagged for low liquidity, high cash burn (~$100M/yr), and dilution risk; combined with a binary H2 2026 catalyst priced into extreme IV, the risk/reward for any structure is unfavorable without a clear entry or income hedge that survives the liquidity gate.\nLet's verify the anti-signal rule: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nDilution: clinical stage biotechs often have >10% dilution risk, but not explicitly stated as >10%. I'll skip.\nCash burn: $100M/yr on $125M cash means ~15 months runway. Not immediate bankruptcy, but high risk.\nLow liquidity: hard gate.\nI will output SKIP.\nScore: 13.\nBreakdown: smart_money: 0, options_flow: 2, catalyst: 8, mispricing: 0, quality: 0, technical: 3.\nReason: Anti-signals for low liquidity, dilution, and high cash burn create unacceptable structural risk; combined with a binary H2 2026 catalyst priced into extreme IV and a >130% YTD run, there is no favorable entry or income structure that justifies the risk.\nCheck thresholds: <45 skip.\nAll good.\nOutput matches required JSON format.\nOne detail: \"low_liquidity\" is in anti_signals_present. The prompt says \"Avg daily volume < $5M (liquidity gate)\". I will treat it as a gate failure.\nI will produce the skip JSON.\nLet's double check the scoring rubric just in case.\nA: 0\nB: 2 (call bias + skew)\nC: 8 (pending catalyst)\nD: 0\nE: 0\nF: 3\nTotal: 13.\nMatches skip criteria.\nReady. \nOutput matches schema.\nNo extra text.\nProceed. \nSelf-Correction/Refinement during thought: \nWait, the prompt says: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nI can articulate that low liquidity makes options execution risky and cash burn/dilution threaten runway before the H2 catalyst. So skip is correct.\nI will format exactly as requested.\nOutput matches. \nProceeds. \n{\n  \"skip\": true,\n  \"score\": 13,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 2,\n    \"catalyst\": 8,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 3\n  },\n  \"reason\": \"Anti-signals for low liquidity, dilution, and high cash burn (~$100M/yr on $125M cash) create unacceptable structural risk; combined with a binary H2 2026 catalyst priced into extreme IV and a >130% YTD run, there is no favorable entry or income structure that justifies the risk.\"\n}\nMatches perfectly. Output matches schema. No markdown. Valid JSON.\nDone. \nProceeds. \n(Self-Correction/Verification during generation prep)\nCheck date rules: Not applicable for skip.\nCheck structure: Only skip JSON.\nAll good. \nOutput matches. \nProceeds. \n[Output Generation] -> *Proceeds*\n</think>\n\n{\n  \"skip\": true,\n  \"score\": 13,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 2,\n    \"catalyst\": 8,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 3\n  },\n  \"reason\": \"Anti-signals for low liquidity, dilution, and high cash burn (~$100M/yr on $125M cash) create unacceptable structural risk; combined with a binary H2 2026 catalyst priced into extreme IV and a >130% YTD run, there is no favorable entry or income structure that justifies the risk.\"\n}",
      "cleaned_content": "{\n  \"skip\": true,\n  \"score\": 13,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 2,\n    \"catalyst\": 8,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 3\n  },\n  \"reason\": \"Anti-signals for low liquidity, dilution, and high cash burn (~$100M/yr on $125M cash) create unacceptable structural risk; combined with a binary H2 2026 catalyst priced into extreme IV and a >130% YTD run, there is no favorable entry or income structure that justifies the risk.\"\n}",
      "tool_calls": null,
      "finish_reason": "stop"
    }
  ],
  "tool_results": [],
  "final_message": "{\n  \"skip\": true,\n  \"score\": 13,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 2,\n    \"catalyst\": 8,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 3\n  },\n  \"reason\": \"Anti-signals for low liquidity, dilution, and high cash burn (~$100M/yr on $125M cash) create unacceptable structural risk; combined with a binary H2 2026 catalyst priced into extreme IV and a >130% YTD run, there is no favorable entry or income structure that justifies the risk.\"\n}",
  "tool_calls_total": 0,
  "walltime_ms": 43746,
  "stop_reason": "stop",
  "completed_at": "2026-06-05T22:26:06.751Z"
}